$1.06 Billion is the total value of Frazier Life Sciences Management, L.P.'s 41 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 11.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $179,733,000 | +10.6% | 8,434,232 | 0.0% | 16.96% | +22.5% | |
| New | HILLEVAX INC | $101,493,000 | – | 9,285,682 | +100.0% | 9.58% | – | |
| KRYS | Buy | KRYSTAL BIOTECH INC | $71,924,000 | +24.8% | 1,095,407 | +26.5% | 6.79% | +38.2% |
| MIRM | MIRUM PHARMACEUTICALS INC | $69,412,000 | -11.6% | 3,566,912 | 0.0% | 6.55% | -2.1% | |
| KDNY | Buy | CHINOOK THERAPEUTICS INC | $62,877,000 | +41.7% | 3,595,026 | +32.6% | 5.93% | +56.9% |
| SNDX | SYNDAX PHARMACEUTICALS INC | $61,480,000 | +10.7% | 3,195,403 | 0.0% | 5.80% | +22.6% | |
| PHAT | PHATHOM PHARMACEUTICALS INC | $49,183,000 | -38.0% | 5,827,415 | 0.0% | 4.64% | -31.3% | |
| SRRA | Sell | SIERRA ONCOLOGY INC | $47,876,000 | -36.2% | 870,636 | -62.8% | 4.52% | -29.4% |
| IMAGO BIOSCIENCES INC | $39,785,000 | -30.5% | 2,971,274 | 0.0% | 3.76% | -23.1% | ||
| PCVX | Sell | VAXCYTE INC | $38,894,000 | -30.3% | 1,787,405 | -22.6% | 3.67% | -22.8% |
| CRNX | CRINETICS PHARMACEUTICALS IN | $26,386,000 | -15.0% | 1,414,823 | 0.0% | 2.49% | -5.9% | |
| TARS | Buy | TARSUS PHARMACEUTICALS INC | $26,098,000 | +9.5% | 1,787,527 | +26.1% | 2.46% | +21.3% |
| ALPN | Sell | ALPINE IMMUNE SCIENCES INC | $25,409,000 | -32.3% | 2,985,757 | -28.7% | 2.40% | -25.1% |
| TCDA | TRICIDA INC | $20,155,000 | +17.8% | 2,082,093 | 0.0% | 1.90% | +30.4% | |
| COGT | Sell | COGENT BIOSCIENCES INC | $18,889,000 | -4.9% | 2,094,154 | -21.0% | 1.78% | +5.3% |
| ANAB | ANAPTYSBIO INC | $18,264,000 | -17.9% | 899,700 | 0.0% | 1.72% | -9.1% | |
| GRCL | Sell | GRACELL BIOTECHNOLOGIES INCsponsored ads | $17,114,000 | +113.2% | 3,111,551 | -9.7% | 1.62% | +136.1% |
| KALV | KALVISTA PHARMACEUTICALS INC | $15,470,000 | -33.2% | 1,572,192 | 0.0% | 1.46% | -26.1% | |
| MRUS | Buy | MERUS N V | $15,259,000 | -8.2% | 673,979 | +7.2% | 1.44% | +1.6% |
| FLACU | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $14,815,000 | -1.2% | 1,501,000 | 0.0% | 1.40% | +9.4% | |
| REPL | Buy | REPLIMUNE GROUP INC | $14,094,000 | +15.8% | 806,267 | +12.5% | 1.33% | +28.3% |
| GRTS | GRITSTONE BIO INC | $12,674,000 | -41.3% | 5,237,348 | 0.0% | 1.20% | -35.0% | |
| ARVN | Buy | ARVINAS INC | $12,010,000 | -34.0% | 285,331 | +5.5% | 1.13% | -26.9% |
| PASG | PASSAGE BIO INC | $11,822,000 | -23.9% | 5,009,219 | 0.0% | 1.12% | -15.6% | |
| VRDN | Sell | VIRIDIAN THERAPEUTICS INC | $11,342,000 | -64.7% | 980,302 | -43.6% | 1.07% | -61.0% |
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $10,604,000 | -32.1% | 3,746,857 | 0.0% | 1.00% | -24.8% | |
| NTLA | INTELLIA THERAPEUTICS INC | $10,543,000 | -28.8% | 203,684 | 0.0% | 1.00% | -21.1% | |
| SLN | SILENCE THERAPEUTICS PLCads | $10,442,000 | -37.6% | 881,173 | 0.0% | 0.98% | -31.0% | |
| Buy | TYRA BIOSCIENCES INC | $9,832,000 | -30.8% | 1,375,065 | +3.6% | 0.93% | -23.4% | |
| STRO | SUTRO BIOPHARMA INC | $9,255,000 | -36.6% | 1,776,479 | 0.0% | 0.87% | -29.9% | |
| ACRS | ACLARIS THERAPEUTICS INC | $5,700,000 | -19.0% | 408,329 | 0.0% | 0.54% | -10.3% | |
| CERE | Buy | CEREVEL THERAPEUTICS HLDNG I | $5,348,000 | +173.6% | 202,260 | +262.2% | 0.50% | +202.4% |
| TRVI | New | TREVI THERAPEUTICS INC | $3,292,000 | – | 1,171,627 | +100.0% | 0.31% | – |
| Sell | PARDES BIOSCIENCES INC | $2,596,000 | -82.7% | 845,636 | -59.4% | 0.24% | -80.9% | |
| IMVT | IMMUNOVANT INC | $2,284,000 | -29.2% | 585,759 | 0.0% | 0.22% | -21.5% | |
| EPIX | ESSA PHARMA INC | $2,183,000 | -49.0% | 692,910 | 0.0% | 0.21% | -43.6% | |
| ISEE | Sell | IVERIC BIO INC | $1,635,000 | -96.0% | 170,000 | -93.0% | 0.15% | -95.6% |
| MTEM | MOLECULAR TEMPLATES INC | $1,253,000 | -73.6% | 1,374,047 | 0.0% | 0.12% | -70.8% | |
| EPZM | EPIZYME INC | $1,087,000 | +27.9% | 739,369 | 0.0% | 0.10% | +43.1% | |
| APTX | APTINYX INC | $1,051,000 | -75.4% | 1,883,244 | 0.0% | 0.10% | -72.8% | |
| NABRIVA THERAPEUTICS PLC | $77,000 | -57.0% | 425,650 | 0.0% | 0.01% | -53.3% | ||
| SRRK | Exit | SCHOLAR ROCK HLDG CORP | $0 | – | -156,000 | -100.0% | -0.17% | – |
| AVDL | Exit | AVADEL PHARMACEUTICALS PLCsponsored adr | $0 | – | -951,814 | -100.0% | -0.55% | – |
| BCYC | Exit | BICYCLE THERAPEUTICS PLCsponsored ads | $0 | – | -603,521 | -100.0% | -2.26% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-10
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS INC | 7 | Q3 2023 | 17.0% |
| MIRUM PHARMACEUTICALS INC | 7 | Q3 2023 | 13.6% |
| PHATHOM PHARMACEUTICALS INC | 7 | Q3 2023 | 8.6% |
| KRYSTAL BIOTECH INC | 7 | Q3 2023 | 7.6% |
| SYNDAX PHARMACEUTICALS INC | 7 | Q3 2023 | 6.3% |
| VAXCYTE INC | 7 | Q3 2023 | 4.8% |
| CRINETICS PHARMACEUTICALS IN | 7 | Q3 2023 | 3.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 3.2% |
| TARSUS PHARMACEUTICALS INC | 7 | Q3 2023 | 2.5% |
| KALVISTA PHARMACEUTICALS INC | 7 | Q3 2023 | 2.1% |
View Frazier Life Sciences Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-07 |
| 13F-HR | 2023-02-03 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-16 |
View Frazier Life Sciences Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.